Vaxcyte, Inc.: shareholders and insiders

PCVXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$59.40

November 17, 2026Market cap $9.4B

What Ploutos Investor adds for Vaxcyte

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Nov 13, 2026, from their own Form 4 filings.

37 Form 4s

Bought on the market

–

nobody

Sold on the market

$14M

5 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan93%
  • The rest7%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $13M by 5 people

  • 2025: no buys, sold $1.0M by 2 people
  • 2026: no buys, sold $13M by 5 people
  • Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops Officer
    Kind10b5-1
  • Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops Officer
    Kind10b5-1
  • Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops Officer
    Kind10b5-1
  • Nov 11, 2026Harpreet S. DhaliwalChief Technical Ops Officer
    Kind10b5-1
  • Nov 2, 2026Elvia CowanSVP, Finance & CAO
    Kind10b5-1
  • Nov 2, 2026Elvia CowanSVP, Finance & CAO
    Kind10b5-1
  • Nov 2, 2026Elvia CowanSVP, Finance & CAO
    Kind10b5-1
  • Nov 2, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Nov 2, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Nov 2, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Oct 5, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Oct 5, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Oct 5, 2026Elvia CowanSVP, Finance & CAO
    Kind10b5-1
  • Oct 5, 2026Elvia CowanSVP, Finance & CAO
    Kind10b5-1
  • Oct 1, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Oct 1, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Oct 1, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Sep 9, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Sep 8, 2026Grant PickeringCHIEF EXECUTIVE OFFICER
    Kind
  • Sep 8, 2026Andrew GuggenhimePRESIDENT AND CFO
    Kind
  • Sep 8, 2026Harpreet S. DhaliwalChief Technical Ops Officer
    Kind
  • Sep 8, 2026Elvia CowanSVP, Finance & CAO
    Kind
  • Sep 8, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind
  • Sep 4, 2026Jim WassilEVP, Chief Scientific Ofc, COO
    Kind10b5-1
  • Sep 4, 2026Luis JodarChief Medical Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by PCVX's officers and directors from 2020 up to November 17, 2025, 6 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

6 Holders over 5%Nov 6, 2026 Latest filing
  • FMRwith 1 more person
    Share of class14.4%
  • JANUS HENDERSON GROUP Ltd.
    Share of class12.1%
  • T. Rowe Price Investment Management, Inc.
    Share of class11.6%
  • RA Capital Management, L.P.with 3 more persons
    Share of class8.90%
  • BlackRock, Inc.
    Share of class7.60%
  • Vanguard Capital Management
    Share of class5.03%
Fell to 5% or less (1)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 27, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • D.E. Shaw
    In the quarter-25%
  • Bridgewater (Dalio)
    In the quarter-20%
  • Citadel Advisors (Griffin)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-51%
  • Renaissance Technologies
    In the quarter
  • AQR Capital
    In the quarter+51%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 9.24% of its shares outstanding were held short, -15.4% since the report before.

Shares held short
14.62M
9.24%
Since the report before17.29M on Sep 30, 2026
-15.4%
2.9
5.05M
More days to cover thanof 4,578 US-listed companies with enough volume
34%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 7.33M
  • Nov 15, 2023: Shares held short 7.27M
  • Nov 30, 2023: Shares held short 7.08M
  • Dec 15, 2023: Shares held short 7.35M
  • Dec 29, 2023: Shares held short 7.62M
  • Jan 12, 2024: Shares held short 8.36M
  • Jan 31, 2024: Shares held short 8.90M
  • Feb 15, 2024: Shares held short 10.65M
  • Feb 29, 2024: Shares held short 8.46M
  • Mar 15, 2024: Shares held short 8.59M
  • Mar 28, 2024: Shares held short 8.26M
  • Apr 15, 2024: Shares held short 8.24M
  • Apr 30, 2024: Shares held short 8.43M
  • May 15, 2024: Shares held short 9.52M
  • May 31, 2024: Shares held short 9.60M
  • Jun 14, 2024: Shares held short 9.68M
  • Jun 28, 2024: Shares held short 10.28M
  • Jul 15, 2024: Shares held short 11.87M
  • Jul 31, 2024: Shares held short 11.50M
  • Aug 15, 2024: Shares held short 11.24M
  • Aug 30, 2024: Shares held short 10.30M
  • Sep 13, 2024: Shares held short 9.71M
  • Sep 30, 2024: Shares held short 9.65M
  • Oct 15, 2024: Shares held short 9.34M
  • Oct 31, 2024: Shares held short 8.93M
  • Nov 15, 2024: Shares held short 9.69M
  • Nov 29, 2024: Shares held short 11.03M
  • Dec 13, 2024: Shares held short 12.60M
  • Dec 31, 2024: Shares held short 14.32M
  • Jan 15, 2025: Shares held short 14.49M
  • Jan 31, 2025: Shares held short 13.53M
  • Feb 14, 2025: Shares held short 13.33M
  • Feb 28, 2025: Shares held short 12.33M
  • Mar 14, 2025: Shares held short 12.61M
  • Mar 31, 2025: Shares held short 12.05M
  • Apr 15, 2025: Shares held short 12.34M
  • Apr 30, 2025: Shares held short 12.04M
  • May 15, 2025: Shares held short 13.49M
  • May 30, 2025: Shares held short 13.20M
  • Jun 13, 2025: Shares held short 13.70M
  • Jun 30, 2025: Shares held short 14.07M
  • Jul 15, 2025: Shares held short 13.62M
  • Jul 31, 2025: Shares held short 13.30M
  • Aug 15, 2025: Shares held short 11.44M
  • Aug 29, 2025: Shares held short 11.51M
  • Sep 15, 2025: Shares held short 11.36M
  • Sep 30, 2025: Shares held short 11.08M
  • Oct 15, 2025: Shares held short 10.01M
  • Oct 31, 2025: Shares held short 8.57M
  • Nov 14, 2025: Shares held short 9.34M
  • Nov 28, 2025: Shares held short 10.30M
  • Dec 15, 2025: Shares held short 10.83M
  • Dec 31, 2025: Shares held short 11.91M
  • Jan 15, 2026: Shares held short 12.10M
  • Jan 30, 2026: Shares held short 11.95M
  • Feb 13, 2026: Shares held short 13.76M
  • Feb 27, 2026: Shares held short 13.26M
  • Mar 13, 2026: Shares held short 13.07M
  • Mar 31, 2026: Shares held short 13.69M
  • Apr 15, 2026: Shares held short 14.36M
  • Apr 30, 2026: Shares held short 14.14M
  • May 15, 2026: Shares held short 13.79M
  • May 29, 2026: Shares held short 14.47M
  • Jun 15, 2026: Shares held short 14.63M
  • Jun 30, 2026: Shares held short 17.47M
  • Jul 15, 2026: Shares held short 14.23M
  • Jul 31, 2026: Shares held short 14.46M
  • Aug 14, 2026: Shares held short 14.80M
  • Aug 31, 2026: Shares held short 15.02M
  • Sep 15, 2026: Shares held short 16.13M
  • Sep 30, 2026: Shares held short 17.29M
  • Oct 15, 2026: Shares held short 14.62M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading71.0% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 71.0% of the shares in the reported trades were short sales, against 72.8% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
71.0%
The 14 beforeOct 9, 2026 – Oct 28, 2026
72.8%
Change
-1.8 pts
Short sales a dayon average, of 583.5K shares
414.4K
More than atof 3,666 US-listed companies, same days
98%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 72.8%
  • Oct 12, 2026: Short sales 83.8%
  • Oct 13, 2026: Short sales 61.8%
  • Oct 14, 2026: Short sales 69.4%
  • Oct 15, 2026: Short sales 55.6%
  • Oct 16, 2026: Short sales 68%
  • Oct 19, 2026: Short sales 71.3%
  • Oct 20, 2026: Short sales 67.2%
  • Oct 21, 2026: Short sales 64.2%
  • Oct 22, 2026: Short sales 79.1%
  • Oct 23, 2026: Short sales 84.9%
  • Oct 26, 2026: Short sales 63.6%
  • Oct 27, 2026: Short sales 90.2%
  • Oct 28, 2026: Short sales 85.8%
  • Oct 29, 2026: Short sales 85%
  • Oct 30, 2026: Short sales 76.2%
  • Nov 2, 2026: Short sales 69.3%
  • Nov 3, 2026: Short sales 78.1%
  • Nov 4, 2026: Short sales 72%
  • Nov 5, 2026: Short sales 77.1%
  • Nov 6, 2026: Short sales 40.3%
  • Nov 9, 2026: Short sales 72.5%
  • Nov 10, 2026: Short sales 55.2%
  • Nov 11, 2026: Short sales 80.4%
  • Nov 12, 2026: Short sales 78.2%
  • Nov 13, 2026: Short sales 56.2%
  • Nov 16, 2026: Short sales 74.3%
  • Nov 17, 2026: Short sales 71%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

1.28M Insiders' shares0.89% Of the company
  • Grant PickeringCHIEF EXECUTIVE OFFICER
    Directly563.1K
  • Andrew GuggenhimePRESIDENT AND CFO
    Directly157.2K
  • Jim WassilEVP, Chief Scientific Ofc, COO
    Directly145.4K
  • Harpreet S. DhaliwalChief Technical Ops Officer
    Directly68.1K
  • Luis JodarChief Medical Officer
    Directly52.6K
  • Mikhail EydelmanSVP, GEN COUNSEL & CORP SEC
    Directly41.7K
  • Elvia CowanSVP, Finance & CAO
    Directly27.9K
  • Heath LukatchDirector
    Directly19.5K
  • Teri LoxamDirector
    Directly12.5K
  • Halley E GilbertDirector
    Directly12.5K
  • Carlos Paya VDirector
    Directly12.5K
  • Anne S DrapeauDirector
    Directly12.5K
  • Jacks LeeDirector
    Directly6,856
  • John FureyDirector
    Directly5,306
  • Olivier BrandicourtDirector
    Directly4,699

A lower bound: it counts only the 15 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

26 ETFs holding it1.19% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund1.19%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.81%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.64%
  • TCAFT. Rowe Price Capital Appreciation Equity ETF
    Weight in the fund0.50%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.29%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.26%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.24%
  • VBKVanguard Small-Cap Growth Index Fund
    Weight in the fund0.24%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.17%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.16%

26 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

331 Managers, Q2 2026$9.7B Value of their positions
  • Q3 2025: Managers 288
  • Q4 2025: Managers 295
  • Q1 2026: Managers 338
  • Q2 2026: Managers 331

Institutional investors by quarter

The fund managers holding PCVX, quarter by quarter, from Q2 2020 to Q2 2025, 21 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 331 managers held 167M shares, worth $9.7B. During the quarter 49 opened a position, 56 closed one, 129 added and 99 trimmed.

The largest holders, Q2 2026

  • FMR
    In the quarter+26%
  • Jupiter Topco
    In the quarter
  • T. Rowe Price Investment Management
    In the quarter+0.7%
  • BlackRock
    In the quarter+10.0%
  • Ra Capital Management
    In the quarter
  • Wellington Management Group
    In the quarter+25%
  • Vanguard Portfolio Management
    In the quarter+5.0%
  • Vanguard Capital Management
    In the quarter+1.3%
  • State Street
    In the quarter+21%
  • Deep Track Capital
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Vaxcyte's filings show?

Who buys and sells is one part of Vaxcyte's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about PCVX's shareholders

Didn't find what you were looking for?

Ask us
Have PCVX's insiders bought or sold?

From Jun 3, 2026 to Nov 13, 2026 Vaxcyte's insiders bought 0 and sold $12M of shares on the market. 100% of the sales were under set 10b5-1 plans.

Which well-known managers hold PCVX?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $81M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.